anti-minor histocompatibility complex (miha) donor t-lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 6, 2017 (NCT03091933)
Timeline
Indications
Studied for
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Lymphoid · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
Mechanism of action
- Unspecified targetTissue restoration
Tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-minor histocompatibility complex (miha) donor t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03154918 | Phase 2 | Jun 1, 2017 | Sichuan University |
| NCT03091933 | Phase 1/Phase 2 (Phase 2) | Feb 6, 2017 | Ciusss de L'Est de l'Île de Montréal |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ciusss de L'Est de l'Île de Montréal | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1